Literature DB >> 17164038

Leukocyte-endothelial cell interactions in chronic vasospasm after subarachnoid hemorrhage.

Gary L Gallia1, Rafael J Tamargo.   

Abstract

Leukocyte-endothelial cell interactions appear to be the root cause of chronic vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). Early clinical observations and indirect experimental evidence suggested an association between inflammation and chronic vasospasm. Early clinical observations in patients with post-hemorrhagic vasospasm included pyrexia, leukocytosis and the presence of circulating immune complexes. Inflammatory infiltrates and increased levels of immunoglobulins and complement fractions within spastic cerebral arteries also provided early evidence for an inflammatory mechanism underlying chronic vasospasm. Early indirect experimental evidence included the ability to reproduce chronic vasospasm with the introduction of inflammatory agents into the subarachnoid space and the inhibition of vasospasm with anti-inflammatory agents. Currently, however, there is an increasing body of direct molecular evidence that demonstrates the pivotal role of leukocyte-endothelial cell interactions in the development of chronic vasospasm. Cell adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), lymphocyte function-associated antigen-1 (LFA-1), macrophage antigen-1 (Mac-1) and endothelial (E)-selectin mediate interactions between circulating leukocytes and cerebral endothelium. Following aSAH, ICAM-1 is up-regulated in cerebral endothelial cells and along with other cell adhesion molecules, can be detected in the serum and cerebrospinal fluid (CSF) of patients with post-hemorrhagic vasospasm. Monoclonal antibody blocking experiments have demonstrated that the prevention of leukocyte extravasation into the subarachnoid space prevents chronic vasospasm. Similarly, drugs like ibuprofen, which prevent ICAM-1 up-regulation and transendothelial cell migration of leukocytes, prevent vasospasm. In this review, we highlight early observations that suggested an association between inflammation and post-hemorrhagic vasospasm, detail the role of leukocyte-endothelial cell interactions in the development of chronic vasospasm and discuss therapeutic implications of an inflammatory etiology of post-hemorrhagic cerebral vasospasm.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17164038     DOI: 10.1179/016164106X152025

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  27 in total

1.  Depletion of Ly6G/C(+) cells ameliorates delayed cerebral vasospasm in subarachnoid hemorrhage.

Authors:  J Javier Provencio; Tamer Altay; Saksith Smithason; Shari Korday Moore; Richard M Ransohoff
Journal:  J Neuroimmunol       Date:  2010-11-06       Impact factor: 3.478

2.  Statins and anti-inflammatory therapies for subarachnoid hemorrhage.

Authors:  Rajat Dhar; Michael Diringer
Journal:  Curr Treat Options Neurol       Date:  2012-04       Impact factor: 3.598

3.  Plasticity of cerebrovascular smooth muscle cells after subarachnoid hemorrhage.

Authors:  Lars Edvinsson; Stine Schmidt Larsen; Aida Maddahi; Janne Nielsen
Journal:  Transl Stroke Res       Date:  2014-01-22       Impact factor: 6.829

4.  Blockade of the MEK/ERK pathway with a raf inhibitor prevents activation of pro-inflammatory mediators in cerebral arteries and reduction in cerebral blood flow after subarachnoid hemorrhage in a rat model.

Authors:  Aida Maddahi; Saema Ansar; Qingwen Chen; Lars Edvinsson
Journal:  J Cereb Blood Flow Metab       Date:  2010-04-28       Impact factor: 6.200

Review 5.  Inflammation in subarachnoid hemorrhage and delayed deterioration associated with vasospasm: a review.

Authors:  J Javier Provencio
Journal:  Acta Neurochir Suppl       Date:  2013

6.  Case report: Intra-procedural aneurysm rupture during endovascular treatment causing immediate, transient angiographic vasospasm.

Authors:  Zoe Zhang; Farhan Siddiq; Wondwossen G Tekle; Ameer E Hassan; Adnan I Qureshi
Journal:  J Vasc Interv Neurol       Date:  2014-06

Review 7.  Unfractionated heparin: multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage.

Authors:  J Marc Simard; David Schreibman; E Francois Aldrich; Bernadette Stallmeyer; Brian Le; Robert F James; Narlin Beaty
Journal:  Neurocrit Care       Date:  2010-12       Impact factor: 3.210

8.  Hemolysate-induced expression of intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 expression in cultured brain microvascular endothelial cells via through ROS-dependent NF-kappaB pathways.

Authors:  Hua Lu; Ji-Xin Shi; Dong-Mei Zhang; Jie Shen; Yi-Xing Lin; Chun-Hua Hang; Hong-Xia Yin
Journal:  Cell Mol Neurobiol       Date:  2008-08-26       Impact factor: 5.046

9.  A Propensity Score-Matched Study of the Use of Non-steroidal Anti-inflammatory Agents Following Aneurysmal Subarachnoid Hemorrhage.

Authors:  Farshad Nassiri; George M Ibrahim; Jetan H Badhiwala; Christopher D Witiw; Alireza Mansouri; Naif M Alotaibi; R Loch Macdonald
Journal:  Neurocrit Care       Date:  2016-12       Impact factor: 3.210

10.  A glutamate receptor antagonist, S-4-carboxyphenylglycine (S-4-CPG), inhibits vasospasm after subarachnoid hemorrhage in haptoglobin 2-2 mice [corrected].

Authors:  Tomas Garzon-Muvdi; Gustavo Pradilla; Jacob J Ruzevick; Matthew Bender; Lindsay Edwards; Rachel Grossman; Ming Zhao; Michelle A Rudek; Gregory Riggins; Andrew Levy; Rafael J Tamargo
Journal:  Neurosurgery       Date:  2013-10       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.